Title:
治療におけるCD89活性化
Document Type and Number:
Japanese Patent JP2014502962
Kind Code:
A
Abstract:
The invention relates to the use of CD89 activating molecules, in particular Fc alpha comprising molecules, and more particularly, IgA, for inducing apoptosis in neutrophils. Anti-CD89 antibodies can alternatively be used. The CD89 activation is beneficial in the treatment of various disorders associated with increases in neutrophils, such as autoimmune disorders, inflammatory disorders, NETosis, or cystic fibrosis.
Inventors:
Stephan von ganton
Mark Verli
Adrian Turcher
Silvia Meschel
Mark Verli
Adrian Turcher
Silvia Meschel
Application Number:
JP2013543743A
Publication Date:
February 06, 2014
Filing Date:
December 14, 2011
Export Citation:
Assignee:
TSE L Bering Actien Gezel Shaft
Uniberg Tate Bern
Uniberg Tate Bern
International Classes:
C07K16/28; A61K39/395; A61P3/04; A61P11/00; A61P19/02; A61P19/04; A61P29/00; A61P37/00; A61P43/00; C12N15/09; C12P21/08
Domestic Patent References:
| JPH09501316A | 1997-02-10 |
Other References:
JOURNAL OF LEUKOCYTE BIOLOGY, vol. Vol. 72, JPN6015048356, 2002, pages pp. 685-691
APMIS, vol. Vol. 113, JPN6017042048, 2005, pages pp. 269-77
APMIS, vol. Vol. 113, JPN6017042048, 2005, pages pp. 269-77
Attorney, Agent or Firm:
Junji Yuda
Noriyuki Takebayashi
Noriyuki Takebayashi